Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in…

Here at AIM at Melanoma, we are fortunate to be frequently asked an important question: What are the different ways…

Welcome to May, a month dedicated to raising awareness about melanoma and skin cancer. At AIM at Melanoma, we’re committed…

In today’s episode, we’re talking about a profoundly touching topic—caring for someone with melanoma. Today, we’re discussing the roles, challenges,…

Melanoma cells are one of the most common cancers that can migrate to the brain, creating a new challenge for…

From the Desk of Samantha Guild Happy Spring! Spring is a season of things new and renewed, and this newsletter…

By Mara Klecker On April 20th, melanoma survivors, their families, and supporters will gather in Dallas for the annual AIM…

The following is an edited and shortened version of our recent interview with Allison Betof Warner, MD, PhD about the…

By Kim Margolin, M.D., FACP, FASCO Note: We are rerunning an update on this TIL therapy article that originally ran…

Ways to Give: Estate Gifts First Article in a Series Here at AIM at Melanoma, we are fortunate to be…